Last night, in an important milestone in the battle against opioid addiction, the Food and Drug Administration (FDA) approved a new, non-opioid, non-addictive class of pain relief medication called Journavx (suzetrigine) that was developed by Vertex Pharmaceuticals. The new drug reduced pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain. It is the result of FDA efforts to develop non-opioid pain relivers through an expedited drug development and review process.
